젠큐릭스

229000KOSDAQ의료용품 및 기타 의약 관련제품 제조업

52.2 / 100

Reference Date: 2026-07-24

Financial Score20.0 / 40

News Sentiment20.2 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 22.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Genex develops molecular diagnostic products and services based on liquid biopsy technology, focusing on cancer prognosis and companion diagnostics. Its key products include the breast cancer prognosis test 'GenesWell BCT' and the lung cancer companion diagnostic test 'GenesWell ddEGFR Mutation Test'. The company is also advancing early cancer detection through liquid biopsy products and CTC technology research.

Number of Employees

75people

Average Salary

57.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.184.0Point

PBR

2.39Industry Average 1.090.0Point

2.2x industry avg (risky)

ROE

-47.25Industry Average -4.893.5Point

9.7x industry avg (excellent)

Debt Ratio

2.55Industry Average 6.866.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲72.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -102.0% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 6Neutral 0Negative 1Average Sentiment Score 80.7

Positive
GC녹십자의료재단, 암 조기검진 디지털 PCR 개발 참여
젠큐릭스 관련 직접적인 영향은 제한적이나, GC녹십자의료재단의 암 조기검진 디지털 PCR 개발 참여는 관련 의료 기술 혁신에 대한 긍정적 신호로 해석됩니다.
Negative
행정처분 딛고 매각 나선 한국신텍스제약…인수자 확보 ‘안갯속’
한국신텍스제약의 매각 추진에도 불구하고, 경영난과 행정처분으로 인한 불확실성이 높아져 부정적인 시장 반응을 보임.
Positive
젠큐릭스, 진스웰 BCT 다기관 연구 국제학술지 게재
젠큐릭스의 유방암 예후진단 검사가 국제 학술지 게재를 통해 유전자 기반 재발 위험 정밀 예측 가능성을 입증, 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 1,669Won52-week high 5,87052-week low 1,428

1-month return0.0Point

1m -22.37% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-14
Neutral[첨부정정]주요사항보고서(회사합병결정)2026-07-09
Neutral[기재정정]합병등종료보고서(자산양수도)2026-06-30
Neutral[기재정정]주요사항보고서(타법인주식및출자증권양도결정)2026-06-30
Neutral[첨부정정]주요사항보고서(회사합병결정)2026-06-26